These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 23238976)

  • 1. Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.
    Bolea I; Gella A; Unzeta M
    J Neural Transm (Vienna); 2013 Jun; 120(6):893-902. PubMed ID: 23238976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.
    Zindo FT; Joubert J; Malan SF
    Future Med Chem; 2015; 7(5):609-29. PubMed ID: 25921401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propargylamine-derived multi-target directed ligands for Alzheimer's disease therapy.
    do Carmo Carreiras M; Ismaili L; Marco-Contelles J
    Bioorg Med Chem Lett; 2020 Feb; 30(3):126880. PubMed ID: 31864798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
    Wang L; Esteban G; Ojima M; Bautista-Aguilera OM; Inokuchi T; Moraleda I; Iriepa I; Samadi A; Youdim MB; Romero A; Soriano E; Herrero R; Fernández Fernández AP; Ricardo-Martínez-Murillo ; Marco-Contelles J; Unzeta M
    Eur J Med Chem; 2014 Jun; 80():543-61. PubMed ID: 24813882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
    Xu YX; Wang H; Li XK; Dong SN; Liu WW; Gong Q; Wang TD; Tang Y; Zhu J; Li J; Zhang HY; Mao F
    Eur J Med Chem; 2018 Jan; 143():33-47. PubMed ID: 29172081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-Propargylamine-hydroxypyridinone hybrids as multitarget agents for the treatment of Alzheimer's disease.
    Guo J; Zhang Y; Zhang C; Yao C; Zhang J; Jiang X; Zhong Z; Ge J; Zhou T; Bai R; Xie Y
    Bioorg Chem; 2021 Aug; 113():105013. PubMed ID: 34062405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel propargylamine-based inhibitors of cholinesterases and monoamine oxidases: Synthesis, biological evaluation and docking study.
    Krátký M; Vu QA; Štěpánková Š; Maruca A; Silva TB; Ambrož M; Pflégr V; Rocca R; Svrčková K; Alcaro S; Borges F; Vinšová J
    Bioorg Chem; 2021 Nov; 116():105301. PubMed ID: 34492558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
    Sterling J; Herzig Y; Goren T; Finkelstein N; Lerner D; Goldenberg W; Miskolczi I; Molnar S; Rantal F; Tamas T; Toth G; Zagyva A; Zekany A; Finberg J; Lavian G; Gross A; Friedman R; Razin M; Huang W; Krais B; Chorev M; Youdim MB; Weinstock M
    J Med Chem; 2002 Nov; 45(24):5260-79. PubMed ID: 12431053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First Synthesis of Racemic
    Guieu B; Lecoutey C; Legay R; Davis A; Sopkova de Oliveira Santos J; Altomare CD; Catto M; Rochais C; Dallemagne P
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33375412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design of new multitarget histamine H
    Łażewska D; Bajda M; Kaleta M; Zaręba P; Doroz-Płonka A; Siwek A; Alachkar A; Mogilski S; Saad A; Kuder K; Olejarz-Maciej A; Godyń J; Stary D; Sudoł S; Więcek M; Latacz G; Walczak M; Handzlik J; Sadek B; Malawska B; Kieć-Kononowicz K
    Eur J Med Chem; 2020 Dec; 207():112743. PubMed ID: 32882609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.
    Samadi A; de los Ríos C; Bolea I; Chioua M; Iriepa I; Moraleda I; Bartolini M; Andrisano V; Gálvez E; Valderas C; Unzeta M; Marco-Contelles J
    Eur J Med Chem; 2012 Jun; 52():251-62. PubMed ID: 22503231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive review of multi-target directed ligands in the treatment of Alzheimer's disease.
    Pathak C; Kabra UD
    Bioorg Chem; 2024 Mar; 144():107152. PubMed ID: 38290187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A molecular approach in drug development for Alzheimer's disease.
    Agatonovic-Kustrin S; Kettle C; Morton DW
    Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of Tryptamine Derivatives as Multi-Target Directed Ligands for Alzheimer's Disease: AChE, MAO-B, and COX-2 as Molecular Targets.
    Asghar S; Mushtaq N; Ahmed A; Anwar L; Munawar R; Akhtar S
    Molecules; 2024 Jan; 29(2):. PubMed ID: 38276568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4,6-Diphenylpyrimidine Derivatives as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase for the Treatment of Alzheimer's Disease.
    Kumar B; Dwivedi AR; Sarkar B; Gupta SK; Krishnamurthy S; Mantha AK; Parkash J; Kumar V
    ACS Chem Neurosci; 2019 Jan; 10(1):252-265. PubMed ID: 30296051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
    Bar-Am O; Amit T; Weinreb O; Youdim MB; Mandel S
    J Alzheimers Dis; 2010; 21(2):361-71. PubMed ID: 20555137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of Antioxidant Enzymes by ASS234, a Multitarget Directed Propargylamine for Alzheimer's Disease Therapy.
    Ramos E; Romero A; Marco-Contelles J; Del Pino J
    CNS Neurosci Ther; 2016 Sep; 22(9):799-802. PubMed ID: 27380946
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.
    Ramsay RR; Tipton KF
    Molecules; 2017 Jul; 22(7):. PubMed ID: 28714881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel benzothiazole derivatives as multitargeted-directed ligands for the treatment of Alzheimer's disease.
    Hafez DE; Dubiel M; La Spada G; Catto M; Reiner-Link D; Syu YT; Abdel-Halim M; Hwang TL; Stark H; Abadi AH
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2175821. PubMed ID: 36789662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer's disease.
    Mao F; Li J; Wei H; Huang L; Li X
    J Enzyme Inhib Med Chem; 2015 Dec; 30(6):995-1001. PubMed ID: 25792506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.